NCCN releases updates to kidney cancer guidelines
The National Comprehensive Cancer Network has announced that its guidelines on kidney cancer have been updated as a result of new therapeutic options available for advanced kidney cancer.
The National Comprehensive Cancer Network (NCCN) has announced that its guidelines on kidney cancer have been updated as a result of new therapeutic options available for advanced kidney cancer. The guidelines panel significantly restructured the treatment recommendations for advanced kidney cancer by delineating treatment by histology and adding treatment options for first- and second-line therapy.
Two kinase inhibitors, sorafenib (Nexavar) and sunitinib (Sutent), were recently approved by FDA and incorporated into the guidelines.
“NCCN guidelines highlight the cutting-edge developments in treatment and are an essential tool for physicians, allied health professionals, patients, and public and private payers,” said William T. McGivney, PhD, CEO of the NCCN.
For a detailed listing of the updates, visit www.nccn.org.
Pediatric urinary microbiome composition is associated with recurrent UTI
September 10th 2024“We hope to learn more about the urinary tract and then be able to correlate predisposition to UTIs or other urological conditions with urobiome composition or marker microbe presence,” says Tatyana A. Sysoeva, PhD.
Advancing bladder cancer care: The importance of integrating mental health support
September 9th 2024"I think the fact that we're having these conversations, that they are being talked about at national meetings, and that we are bringing the patient voice into this is hugely important," says Mary W. Dunn, MSN, NP-C, OCN, RN.
